Medicare has proposed limiting coverage of Aduhelm, a costly new drug to treat Alzheimer’s disease, and prominent groups are pressing to make it more available. But among those facing the disease, the outlook is nuanced.

Join The Ecosystem

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}